Deborah A Higgins

US Patent:

58405640, Nov 24, 1998

Filed:

Sep 9, 1997

Appl. No.:

8/926362

Inventors:

Stephen Anderson - Princeton NJ
William F. Bennett - San Mateo CA
David Bottstein - Belmont CA
Deborah L. Higgins - San Mateo CA
Nicholas F. Paoni - Moraga CA
Mark J. Zoller - San Francisco CA

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

C07H 2104
C12N 964

US Classification:

435226

Abstract:

Tissue plasminogen activator (t-PA) zymogens and variants are prepared, including a fibrinolytically active variant of t-PA that has an amino acid alteration at a site within the protease domain of t-PA as compared with the corresponding wild-type t-PA, which alteration renders the variant zymogenic in the presence of plasmin-degraded fibrinogen, and/or fibrin (or plasma clot) specific, as compared to the corresponding wild-type t-PA. DNA sequences can be prepared that encode the zymogens and variants, as well as expression vectors incorporating the DNA sequences, and host cells transformed with the expression vectors. The zymogens and variants may be used in a pharmaceutical preparation to treat a vascular disease or condition or to prevent fibrin deposition or adhesion formation or reformation in mammals.

US Patent:

57285675, Mar 17, 1998

Filed:

Aug 1, 1996

Appl. No.:

8/662891

Inventors:

Stephen Anderson - Princeton NJ
William F. Bennett - San Mateo CA
David Botstein - Belmont CA
Deborah L. Higgins - San Mateo CA
Nicholas F. Paoni - Moraga CA
Mark J. Zoller - San Francisco CA

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

C12N 964
C12N 1558
C12N 1570
C12N 1586

US Classification:

435226

Abstract:

Tissue plasminogen activator (t-PA) zymogens and variants are prepared, including a fibrinolytically active variant of t-PA that has an amino acid alteration at a site within the protease domain of t-PA as compared with the corresponding wild-type t-PA, which alteration renders the variant zymogenic in the presence of plasmin-degraded fibrinogen, and/or fibrin (or plasma clot) specific, as compared to the corresponding wild-type t-PA. DNA sequences can be prepared that encode the zymogens and variants, as well as expression vectors incorporating the DNA sequences, and host cells transformed with the expression vectors. The zymogens and variants may be used in a pharmaceutical preparation to treat a vascular disease or condition or to prevent fibrin deposition or adhesion formation or reformation in mammals.

US Patent:

55209130, May 28, 1996

Filed:

Jul 6, 1993

Appl. No.:

8/088451

Inventors:

Stephen Anderson - Princeton NJ
William F. Bennett - San Mateo CA
David Botstein - Belmont CA
Deborah L. Higgins - San Mateo CA
Nicholas F. Paoni - Moraga CA
Mark J. Zoller - San Francisco CA

Assignee:

Genentech, Inc. - San Francisco CA

International Classification:

C12N 950
C12N 964
A61K 3849
C07H 1512

US Classification:

424 9464

Abstract:

Tissue plasminogen activator (t-PA) zymogens and variants are prepared, including a fibrinolytically active variant of t-PA that has an amino acid alteration at a site within the protease domain of t-PA as compared with the corresponding wild-type t-PA, which alteration renders the variant zymogenic in the presence of plasmin-degraded fibrinogen, and/or fibrin (or plasma clot) specific, as compared to the corresponding wild-type t-PA. DNA sequences can be prepared that encode the zymogens and variants, as well as expression vectors incorporating the DNA sequences, and host cells transformed with the expression vectors. The zymogens and variants may be used in a pharmaceutical preparation to treat a vascular disease or condition or to prevent fibrin deposition or adhesion formation or reformation in mammals.

US Patent:

56141904, Mar 25, 1997

Filed:

Apr 26, 1995

Appl. No.:

8/429364

Inventors:

Stephen Anderson - Princeton NJ
William F. Bennett - San Mateo CA
David Botstein - Belmont CA
Deborah L. Higgins - San Mateo CA
Nicholas F. Paoni - Moraga CA
Mark J. Zoller - San Francisco CA

Assignee:

Genentech, Inc. - So. San Francisco CA

International Classification:

A61K 3849
C12N 950
C12N 964
C12N 1555

US Classification:

424 9464

Abstract:

Tissue plasminogen activator (t-PA) zymogens and variants are prepared, including a fibrinolytically active variant of t-PA that has an amino acid alteration at a site within the protease domain of t-PA as compared with the corresponding wild-type t-PA, which alteration renders the variant zymogenic in the presence of plasmin-degraded fibrinogen, and/or fibrin (or plasma clot) specific, as compared to the corresponding wild-type t-PA. DNA sequences can be prepared that encode the zymogens and variants, as well as expression vectors incorporating the DNA sequences, and host cells transformed with the expression vectors. The zymogens and variants may be used in a pharmaceutical preparation to treat a vascular disease or condition or to prevent fibrin deposition or adhesion formation or reformation in mammals.

US Patent:

58211055, Oct 13, 1998

Filed:

Oct 17, 1996

Appl. No.:

8/733124

Inventors:

Stephen Anderson - Princeton NJ
William F. Bennett - San Mateo CA
Deborah L. Higgins - San Mateo CA
Nicholas F. Paoni - Moraga CA
Mark J. Zoller - San Francisco CA

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

C12N 964

US Classification:

435226

Abstract:

Tissue plasminogen activator (t-PA) zymogens and variants are prepared, including a fibrinolytically active variant of t-PA that has an amino acid alteration at a site within the protease domain of t-PA as compared with the corresponding wild-type t-PA, which alteration renders the variant zymogenic in the presence of plasmin-degraded fibrinogen, and/or fibrin (or plasma clot) specific, as compared to the corresponding wild-type t-PA. DNA sequences can be prepared that encode the zymogens and variants, as well as expression vectors incorporating the DNA sequences, and host cells transformed with the expression vectors. The zymogens and variants may be used in a pharmaceutical preparation to treat a vascular disease or condition or to prevent fibrin deposition or adhesion formation or reformation in mammals.

US Patent:

52621707, Nov 16, 1993

Filed:

Oct 3, 1991

Appl. No.:

7/770510

Inventors:

Stephen Anderson - Princeton NJ
William F. Bennett - San Mateo CA
David Botstein - Belmont CA
Deborah L. Higgins - San Mateo CA
Nicholas F. Paoni - Moraga CA
Mark J. Zoller - San Francisco CA

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

C12N 964
C12N 1558
A61K 37547

US Classification:

424 9464

Abstract:

Tissue plasminogen activator (t-PA) zymogens and variants are prepared, including a fibrinolytically active variant of t-PA that has an amino acid alteration at a site within the protease domain of t-PA as compared with the corresponding wild-type t-PA, which alteration renders the variant zymogenic in the presence of plasmin-degraded fibrinogen, and/or fibrin (or plasma clot) specific, as compared to the corresponding wild-type t-PA. DNA sequences can be prepared that encode the zymogens and variants, as well as expression vectors incorporating the DNA sequences, and host cells transformed with the expression vectors. The zymogens and variants may be used in a pharmaceutical preparation to treat a vascular disease or condition or to prevent fibrin deposition or adhesion formation or reformation in mammals.

US Patent:

51089017, Apr 28, 1992

Filed:

Jul 24, 1989

Appl. No.:

7/384608

Inventors:

Stephen Anderson - Princeton NJ
William F. Bennett - San Mateo CA
David Botstein - Belmont CA
Deborah L. Higgins - San Carlos CA
Nicholas F. Paoni - Moraga CA
Mark J. Zoller - San Francisco CA

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

C12N 950
C12N 964
C12Q 138
C07H 1512

US Classification:

435 23

Abstract:

Tissue plasminogen activator (t-PA) zymogens and variants are prepared, including a fibrinolytically active variant of t-PA that has an amino acid alteration at a site within the protease domain of t-PA as compared with the corresponding wild-type t-PA, which alteration renders the variant zymogenic in the presence of plasmin-degraded fibrinogen, and/or fibrin (or plasma clot) specific, as compared to the corresponding wild-type t-PA. DNA sequences can be prepared that encode the zymogens and variants, as well as expression vectors incorporating the DNA sequences, and host cells transformed with the expression vectors. The zymogens and variants may be used in a pharmaceutical preparation to treat a vascular disease or condition or to prevent fibrin deposition or adhesion formation or reformation in mammals.

US Patent:

57704260, Jun 23, 1998

Filed:

Jun 12, 1996

Appl. No.:

8/660986

Inventors:

Stephen Anderson - Princeton NJ
William F. Bennett - San Mateo CA
David Botstein - Belmont CA
Deborah L. Higgins - San Mateo CA
Nicholas F. Paoni - Moraga CA
Mark J. Zoller - San Francisco CA

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

A61K 3848
C12N 964
C12N 1563

US Classification:

435226

Abstract:

Tissue plasminogen activator (t-PA) zymogens and variants are prepared, including a fibrinolytically active variant of t-PA that has an amino acid alteration at a site within the protease domain of t-PA as compared with the corresponding wild-type t-PA, which alteration renders the variant zymogenic in the presence of plasmin-degraded fibrinogen, and/or fibrin (or plasma clot) specific, as compared to the corresponding wild-type t-PA. DNA sequences can be prepared that encode the zymogens and variants, as well as expression vectors incorporating the DNA sequences, and host cells transformed with the expression vectors. The zymogens and variants may be used in a pharmaceutical preparation to treat a vascular disease or condition or to prevent fibrin deposition or adhesion formation or reformation in mammals.